TNFSF10 and cancer: Antiproliferative treatment with PLX4720 could not be implemented within the small therapeutic window predicted and the 17-AAG inhibitor could not eradicate tumour cells under short time exposure at low concentration, their combination with an apoptotic agent like TRAIL proved essential and could intensify the results on cancer cell death.